Comparing new oral treatments for skin sores from leishmaniasis
Treatments studied
Part of Infections, Skin clinical trials.
This study tests two new oral medicines (called LXE408) against an existing oral treatment (miltefosine) for people with a first episode of localized cutaneous leishmaniasis (skin sores caused by a parasite). The goal is to see if the new medicines are safe and work better at healing the sores.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older and weigh more than 110 pounds (50 kg).
- This must be your first time having cutaneous leishmaniasis (skin sores from the infection).
- You should have 6 or fewer skin sores, with at least one sore that is larger than a small coin.
- The sores must have appeared within the last 6 months.
- You must be willing to have the infection confirmed through a skin test or lab test.
- You cannot have other serious health conditions, such as heart, kidney, liver, or eye problems, or a weakened immune system.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study compares different drugs to find the best one for treating cutaneous leishmaniasis, a skin infection that causes sores. You might get one of several treatments, and the goal is to see which works best and is safest for patients like you.
This trial tests how well miltefosine works for people with leishmaniasis, a skin infection from a parasite. It aims to find the best way to use this medicine to help patients get better.
This study tests a gel containing miltefosine (a medicine) applied directly to the skin sores caused by cutaneous leishmaniasis. The goal is to see if the gel is safe and works to clear the sores.
This trial tests a combination of two medicines—inhaled pentamidine and oral miltefosine—to treat mucosal leishmaniasis, a parasitic infection of the nose, mouth, and throat. It may be an option for people in Bolivia who have not been treated recently.
This trial tests whether adding a special laser treatment (fractional CO₂ laser) to the standard injected medicine (Glucantime) helps heal skin sores from a parasite infection better than the medicine alone. It may offer a more effective way to clear the sores and improve healing.
This study tests whether adding a special medicine (an antimicrobial adjuvant) to the standard treatment for complicated skin sores caused by leishmaniasis can improve healing. It is for people in Ethiopia with sores that are large, many, or in sensitive areas.
Hear when a new Localized Cutaneous Leishmaniasis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.